Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Several rheumatoid arthritis (RA) susceptibility variants map close to genes involved in the tumor necrosis factor (TNF) signaling pathway, prompting the investigation of RA susceptibility variants in studies of predictors of response to TNF blockade.
|
21952740 |
2012 |
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
After lenalidomide treatment, genes involved in the tumor necrosis factor (TNF) signaling pathway that were upregulated in the patients before treatment decreased to the healthy control baseline expression level.
|
22608605 |
2012 |
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Chondrocytes from normal joint cartilage were cultured <i>in vitro</i> for interleukin 6 (IL6) or tumor necrosis factor (TNF) treatment and si-NR4A1 transfection, after which the possible mechanism involving NR4A1 was analyzed.
|
28337303 |
2017 |
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Functional enrichment analyses suggested that the upregulated genes were markedly enriched in inflammation-related biological processes, as well as in the tumor necrosis factor (TNF) signaling pathway, cytokine-cytokine receptor interactions, complement and coagulation cascades, and in the chemokine signaling pathway.
|
31044753 |
2020 |
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Deletion of key genes within the tumor necrosis factor (TNF) signaling, interferon-γ (IFN-γ) signaling, and antigen presentation pathways provided protection of tumor cells from CD8<sup>+</sup> T cell-mediated killing and blunted antitumor immune responses in vivo.
|
29776993 |
2018 |
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Interferon (IFN)γ release was evaluated by ELISA whereas cytokine profile [IFNγ, tumor necrosis (TNF)α, interleukin (IL)2] and phenotype (CD45RA, CCR7) by flow cytometry.
|
28837654 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
L19-TNFα/L19-IL2 combination therapy eradicated tumors in J558L myeloma BALB/c mice likely via TNFα-induced tumor necrosis and L19-TNFα/L19-IL2-mediated local cellular immune reactions.
|
29327244 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumour necrosis factor (TNF) signalling is mediated via two receptors, TNF-receptor 1 (TNFR1) and TNF-receptor 2 (TNFR2), which work antithetically to balance CNS immune responses involved in autoimmune diseases such as multiple sclerosis.
|
30206422 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition, there were significant differences in interleukin (IL)-6 and tumor necrosis (TNF)-α concentrations at 24 h after hepatectomy between the two groups, and mean arterial pressure, heart rate, and the bispectral index were also significantly lower in D group than in C group (p < .05).
|
31669050 |
2020 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TNF-α inhibition resulted in suppression of IL-6 and IL-8 in parallel with clinical improvement in all anti-TNF-treated subjects, but was also associated with elevated TNF-α and IL-17 in etanercept-treated subjects.
|
26934060 |
2016 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additionally, the majority of DEGs were mainly enriched in NF-kappa β (NF-kβ) signaling pathway and tumor necrosis factor (TNF) signaling pathway.
|
31277141 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Analysis of tumor necrosis factor (TNF) signaling pathway which regulates the transcription factor Nuclear Factor κB (NF-κB) using this method identifies two types of incorrect cell decisions called false alarm and miss.
|
28379950 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
LPS, interleukin-1 (IL-1), and to a lesser extent tumor necrosis factor (TNF) significantly decreased MTP mRNA levels in hamster liver.These effects required several hours.
|
9643353 |
1998 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis indicated that these proteins mainly were involved in the process of cytokine-cytokine receptor interaction, transforming growth factor-β (TGF-β) signaling pathway, pathways in cancer, tumor necrosis factor (TNF) signaling pathway, and mitogen-activated protein kinase (MAPK) signaling pathway.
|
29344174 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Signaling pathway analysis revealed that these DEGs were mainly involved in apoptosis, hypoxia‑inducible factor (HIF) 1a pathway, innate immune system, tumor necrosis factor (TNF) signaling pathway, cytokine‑cytokine receptor interaction, and other signal transduction pathways.
|
28944843 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
3xTg-AD mice had an increased pro-inflammatory response characterised by the production of pro-inflammatory mediators such as tumour necrosis TNF-α, IL-6, CCL5 and CXCL-1, as well as an increase in immune cell infiltration to the sites of infection.
|
28284226 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that these DEGs were mainly associated with metabolic pathways, the peroxisome proliferator-activated receptor (PPAR) signaling pathway, regulation of lipolysis in adipocytes, the tumor necrosis factor (TNF) signaling pathway, and the FoxO signaling pathway.
|
30424473 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PubMed literature searches were conducted using combinations of search terms including ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, switch/switching, drug survival, and TNF/tumor necrosis factor to identify published articles with data on outcomes related to switching biologic therapies in patients with axSpA.
|
28551170 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These effects can be explained by the diverse cellular responses TNF can initiate through distinct signal transduction pathways, opening the way for more selective targeting of TNF signalling in cancer therapy.
|
23460481 |
2013 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Moreover, reciprocal bone marrow transplantation experiments using TNF receptor-deficient mice revealed that TNF signals are equally pathogenic when directed independently to either bone marrow-derived or tissue stroma cell targets.
|
12486099 |
2002 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In particular, pro-apoptotic tumor necrosis factor (TNF) signals are blocked by proteins that are induced by NF-kappaB such as TNFR-associated factor 1 (TRAF1).
|
10692572 |
2000 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Consecutive CD patients with intestinal strictures that initiated treatment with anti-tumor necrosis alpha (anti-TNF) between June 2012 and April 2017 with MRE adjacent to treatment onset were retrospectively collected.
|
29779158 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pathway analysis suggests that tumor necrosis factor (TNF) signaling pathway, NOD-like receptor pathway, and cytokine-cytokine receptor interaction may be involved in ALI.
|
30979832 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The tumor necrosis factor (TNF) signaling pathway is a classical immune system pathway that plays a key role in regulating cell survival and apoptosis.
|
25912078 |
2015 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumor necrosis factor (TNF) signaling is required for inflammatory nociceptive (pain) sensitization in Drosophila and vertebrates.
|
28492538 |
2017 |